{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-097741","form_type":"8-K/A","ticker":"NKTX","cik":"0001787400","company_name":"Nkarta, Inc.","filed_at":"2024-08-16T23:59:59+00:00","discovered_at":"2026-05-14T18:03:14.527013+00:00","generated_at":"2026-05-31T08:52:32.221081+00:00","sec_items":["1.01","2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Nkarta Q2 net loss $25M; cash $426.7M; NKX019 autoimmune trial Ntrust-2 to start by year-end","bullets":["Net loss of $25.0M ($0.34 diluted EPS); R&D expense $23.1M, G&A $7.6M.","Cash & investments $426.7M expected to fund operations into late 2027.","FDA cleared second IND for NKX019 in autoimmune disease; Ntrust-2 enrollment for systemic sclerosis, myositis, vasculitis expected by year-end 2024.","Preliminary Ntrust-1 and Ntrust-2 data planned for 2025; NHL 7-day dosing cohort enrollment completed, data due late 2024.","Nadir Mahmood joined as President; David Shook promoted to CMO, Head of R&D."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-097741","json":"https://secwatch.observer/filing/0000950170-24-097741.json","markdown":"https://secwatch.observer/filing/0000950170-24-097741.md","text":"https://secwatch.observer/filing/0000950170-24-097741.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1787400/000095017024097741/0000950170-24-097741-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1787400/000095017024097741/nktx-20240813.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T08:52:32.221081+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}